Table 1: Patient characteristics, retention in care and loss to follow-up from urban ART program in Ghana.
Patient Characteristics |
Patient Category (N = 370) |
Retention in care |
Loss to follow-up |
Gender |
Female 258 (69.3%) |
188 (72.9%) |
70 (27.1%) |
Male 112 (30.7%) |
72 (64.3%) |
40 (35.7%) |
|
Age Group (Years) |
21-40 200 (54.1%) |
135 (67.5%) |
65 (32.5%) |
41-60 160 (43.2%) |
118 (73.8%) |
42 (26.2%) |
|
61-80 10 (2.7%) |
7 (70.0%) |
3 (30.0%) |
|
Occupation |
Employed 333 (90%) |
240 (72.1%) |
93 (27.9%) |
Unemployed 37 (10%) |
20 (54.1%) |
17 (45.9%) |
|
Education |
Primary 199 (53.8%) |
150 (75.4%) |
49 (24.6%) |
Secondary 28 (7.6%) |
16 (57.1%) |
12 (42.9%) |
|
Tertiary 16 (4.3%) |
8 (50%) |
8 (50%) |
|
Uneducated 127 (34.3%) |
86 (67.7%) |
41 (32.3%) |
|
Marital status |
Divorced 72 (19.5%) |
60 (83.3%) |
12 (16.7%) |
Married 146 (39.5%) |
91 (62.3%) |
55 (37.7%) |
|
Single 89 (24.1%) |
59 (66.3%) |
30 (33.7%) |
|
Widowed 63 (17.0%) |
50 (79.4%) |
13 (20.6%) |
|
ART initiation Regimen |
AZT/3TC/EFV 88 (23.8%) |
54 (61.4%) |
34 (38.6%) |
AZT/3TC/NVP 109 (29.5%) |
79 (72.5%) |
30 (27.5%) |
|
TDF/3TC/EFV 114 (30.8%) |
86 (75.4%) |
29 (26.4%) |
|
TDF/3TC/NVP 59 (15.9%) |
42 (71.2%) |
17 (28.8%) |
Note: TDF is tenofovir disoproxyl fumarate, AZT is azidothymidine (zidovudine), 3 TC is lamivudine, NVP is nevirapine and EFV is efavirenz